Filler Vascular Occlusion: Warning Signs, Treatment and Prevention
Vascular occlusion is the most serious dermal filler complication. Warning signs, why hyaluronidase matters, blindness risk by area, and how to choose a safe injector.
Vascular occlusion happens when filler is accidentally injected into, or presses on, a blood vessel and blocks blood flow. The short answer: it's rare but is the most serious filler risk, and it needs emergency treatment. For hyaluronic acid fillers, the antidote is the enzyme hyaluronidase, given right away in high doses.
What the FDA says
The FDA calls unintentional injection into a blood vessel the most concerning risk of dermal fillers. The chances are low, but complications can be serious and permanent, including tissue death (necrosis), vision problems including blindness, and stroke (FDA: dermal fillers).
Warning signs
Call your injector or seek emergency care immediately if you notice, during or after injection:
- Severe pain that's out of proportion to the procedure
- Skin that turns white (blanching), then dusky, blue or mottled
- Slow return of color when the skin is pressed
- Blisters or dark patches in the days after
- Any change in vision, eye pain, drooping eyelid, or double vision
- Stroke symptoms such as weakness, numbness or trouble speaking
Blindness risk by area
A 2024 review added 365 new cases of vision loss after filler, published between 2018 and 2023 (Doyon et al., Aesthet Surg J, 2024):
| Finding | Result |
|---|---|
| Highest-risk sites | Nose (40.6%), forehead (27.7%), glabella between the brows (19.0%) |
| Filler type | Hyaluronic acid in 79.6% of cases |
| Stroke-like features | 19.2% |
| Full vision recovery | 6.0% |
| No vision recovery | 68.2% |
No treatment was significantly linked to better vision outcomes, which is why prevention and immediate action matter so much.
How it's treated
- Hyaluronidase: A 2024 review said vascular occlusion and blindness need immediate, high-dose hyaluronidase. It noted there are limited controlled data but growing clinical experience, and that ultrasound guidance can improve treatment (Kroumpouzos et al., JMIR Dermatol, 2024).
- Non-HA fillers such as calcium hydroxylapatite or poly-L-lactic acid can't be dissolved with hyaluronidase, which makes complications harder to reverse.
- Vision loss is an emergency needing an eye specialist straight away.
Prevention: choosing an injector
The FDA advises treating filler as a medical procedure, asking about your provider's training and experience, never self-injecting, and not buying filler online (FDA: dermal fillers). Also ask:
- Do you keep hyaluronidase on site, and do you have a vascular occlusion protocol?
- Do you use cannulas or ultrasound in high-risk areas?
- What's your plan if something goes wrong after hours?
- Which FDA-approved product will you use, and is it approved for this area?
More detail on vision loss
- Growing case numbers: The same research group previously reviewed 98 cases in 2015 and 48 more in 2019, before adding 365 new cases in the 2024 update (Doyon et al., Aesthet Surg J, 2024).
- Common accompanying signs: skin changes (73.2%), drooping eyelid (56.2%), restricted eye movement (44.1%) and pain (31.2%).
- Treatments used: hyaluronidase injected near the filler site (70.1%), systemic steroids (57.3%) and thrombolytic therapy into an artery (56.0%). None was significantly linked to better vision.
- Best predictor of recovery: some vision still being present at onset.
Hyaluronidase for other filler problems
The 2024 hyaluronidase review also covers non-emergency problems. A bluish tint under the skin (the Tyndall effect), non-inflamed lumps and allergic reactions are treated with low to moderate doses. Inflamed nodules may need antibiotics as well, and the review says hyaluronidase may be tried for granulomas that haven't responded to steroid injections (Kroumpouzos et al., JMIR Dermatol, 2024).
Products and devices to avoid
The FDA says needle-free devices aren't approved for injecting dermal fillers, warns of serious injuries linked to them, and notes that no dermal fillers are approved for over-the-counter use (FDA: dermal fillers).
Frequently asked questions
How common is it? The FDA describes the chance as low. Exact rates aren't well established.
Can it happen days later? Most signs appear during or soon after injection, but skin changes can develop over the following days.
Is the nose filler safe? The nose is the highest-risk site for blindness in the published cases; choose an experienced injector and weigh the risks.
This article is for educational purposes only and is not medical advice. Talk to a board-certified dermatologist about your situation.
Sources
- Doyon VC et al. Update on blindness from filler: review of prognostic factors, management approaches, and a century of published cases. Aesthet Surg J. 2024. PubMed
- Kroumpouzos G et al. Hyaluronidase for dermal filler complications: review of applications and dosage recommendations. JMIR Dermatol. 2024. PubMed
- U.S. Food and Drug Administration. Dermal fillers (soft tissue fillers)
